AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUL 4 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - In addition to its anticancer effects, all-trans-retinoic acid (ATRA) can help breast cancer patients maintain hemostasis before surgery, researchers in Italy report.
Dr. Anna Falanga and colleagues at Riuniti Hospital in Bergamo, the University of Genoa and the National Cancer Institute in Genoa, and Roche S.p.A. in Monza performed a study to "evaluate whether all-trans-retinoic acid (ATRA) is able to modulate the hemostatic system in [breast cancer] patients with solid tumors".
ATRA administration reduced the elevated levels of coagulation activity seen during tamoxifen treatment, Falanga and coauthors found.
Patients treated with tamoxifen alone showed increased levels of factor VIIa, thrombin-antithrombin complex, and prothrombin fragment 1+2, they said. While advanced breast cancer patients normally have heightened coagulation activity compared with healthy controls, tamoxifen monotherapy produced significant additional elevations in levels of these hypercoagulation markers.
By contrast, ATRA monotherapy had no effect on coagulation activity. Moreover, ATRA significantly attenuated tamoxifen-induced elevation of hypercoagulability marker levels, study data showed.
Fibrinolysis ...